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Abstract We sought to profile the epidemiological implica-
tion of human immunodeficiency virus (HIV) and hepatitis C
virus (HCV) co-infection from South and Southeast Asia by
reviewing original studies reporting prevalence of HIV-HCV
co-infection and their risk factors. Thirteen papers cited in the
PubMed database and published in 2012 and 2013 were
reviewed. The overall HCV co-infection prevalence ranged
broadly from 1.2 % to 98.5 % among HIV-positive people in
South and Southeast Asia. Among HCV seropositive blood
donors in Nepal, 5.75 % had HIV co-infection. Injecting drug
use (IDU) was one of the key risk factors of co-infection, with
HCV infection reaching 89.8 % and 98.5 % among HIV-
positive injecting drug users in Vietnam. The most recent data
from South and Southeast Asia suggest the urgency of imple-
mentation of comprehensive prevention and control strategies
of HIV-HCV co-infection.
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Introduction
The 150 million people chronically infected with hepatitis C
virus (HCV) suggest a 2.3 % global prevalence, higher even
than the 35.3 million people living with human immunodefi-
ciency virus (HIV), about 0.54 % prevalence. However, death
rates are inverted with about 350,000 deaths/year from HCV-
related liver diseases to 1.6 million deaths/year due to HIV/
AIDS, as estimated in 2013 by the World Health Organization
(WHO) and the Joint United Nations Program on HIV/AIDS
(UNAIDS) [1•, 2•].
Given sexual, blood, and perinatal transmission routes,
HIV and HCV can be expected to be transmitted in similar
at-risk populations. Reports are variable, but reports range
from 7-30 % HCV co-infection among HIV patients [3–7]
and 6-10 % HIV co-infection among HCV patients [5, 8••].
Co-infections influence each other and affect the pathogenesis
and even causes of death for HIV-HCV infected persons,
complicating both treatment and even prevention strategies
[9, 10].
The estimated number of HIV cases in 19 countries of
South and Southeast Asia ranks second just after Sub-
Saharan Africa [2•]. Many of these nations have made sub-
stantial efforts to combat HIV/AIDS with a variety of educa-
tion and prevention strategies, including efforts towards stig-
ma reduction, interventions targeting commercial sex workers
(CSW), injection drug users (IDU), expanded antiretroviral
treatment (ART), and ensuring a safe blood supply, among
others.
HCV infections are serious in these same countries, too,
due to blood transfusions and IDU [11, 12]. With the expan-
sion of the HIV epidemic, increased awareness, and better
diagnostic capacities, more HIV-HCV co-infections have
been reported with increasing frequency [11, 13–15, 16••,
17••, 18••]. Many studies have introduced these co-
epidemics, analyzed the risk factors, discussed treatment,
and suggested strategies of prevention and control in individ-
ual countries. While a few reviews included South and
Southeast Asia [19, 20], there has been little targeted attention
on HIV-HCV co-infection specifically for South and
Southeast Asia.
Our paper aims uses recently published literature to provide
a profile of the epidemiological circumstances for HIV-HCV
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prevalence and risk factors in South and Southeast Asia. We
hope this stimulates increased attention to both prevention and
clinical care for these highly populous nations.
Methods
Search Strategy The literature onHIV-HCV co-infection pub-
lished in English in 2012 and 2013 was searched with the
PubMed database. Keywords used in the database search
included: [(hepatitis C or HCV) AND (HIV OR AIDS)
AND (2012 OR 2013)] AND [(South Asia or Southeast
Asia) or (individual country names of South and Southeast
Asia)] (Table 1): All publications were sorted with an
Endnote® file (Endnote X4®, Thomson Reuters, San
Francisco, CA: Full texts were obtained from ProQuest®
Health & Medical through the Chinese Center for Disease
Control and Prevention.
Study Selection The following criteria were used to select
studies: original study on HIV-HCV co-infection; available
prevalence rate of co-infection and/or odds ratio (OR) for
putative risk factors; eligible countries of South and
Southeast Asia. All titles and abstracts were reviewed to
decide the inclusion of the eligible papers. Full texts were also
reviewed whenever necessary, to check the data details and to
judge the relevance of the epidemiological observations of
HIV-HCV co-infection.
Results
Result of Literature Search A total of 23 and 39 papers were
found in South and Southeast Asia in 2012 and 2013, respec-
tively, of which 54 were unique (8 duplicates). A further 10
papers were excluded because they were not actually studies
in South and Southeast Asia. Nine more papers were excluded
due to containing only HIVor HCV information. Reviews of
the abstracts and full texts of the remaining 35 papers led to
further exclusion of 22 papers which had no data regarding
HIV-HCV co-infection. Thus a total of 13 papers met the
review needs [8••, 16••, 17••, 18••, 21••, 22••, 23••, 24••,
25••, 26••, 27••, 28••, 29••].
Description of Studies Among the 13 studies shown in
Table 2, two South Asian studies were conducted in India
and three in Nepal. Among eight Southeast Asian studies, two
were in Vietnam, one in Cambodia, one in Myanmar, two in
Thailand, and two in Indonesia. Except for one retrospective
cohort and one case control study, 11 were designed as cross-
sectional studies. The sample size of the studies ranged widely
from 126 to 16,124. Eight studies used HIV-positive samples
to assess HCV prevalence including one study among HIV-
infected IDUs. Four studies used high risk populations, in-
cluding one study among CSWs, one study among IDU
inmates, and one among both CSWs and IDUs. The last study
was conducted among blood donors who were HCV
seropositive.
HIV-HCV Co-infection Prevalence
The overall HIV-HCV co-infection prevalence among HIV-
positive persons ranged broadly from 1.2 % to 98.5 % in
South and Southeast Asia, as shown in Table 2. In six studies
testing HIV-positive samples, the HIV-HCV co-infection rate
was relatively higher in Indonesia, Nepal and Vietnam, rang-
ing between 34.1 % and 98.5 % [18••, 21••, 22••, 24••, 27••].
Particularly in Vietnam, it reached 89.8 % and 98.5 % among
HIV-positive IDUs [22••, 27••]. In Myanmar and Thailand,
the HIV-HCV co-infection rate among HIV-infected persons
was comparatively lower than in Indonesia, Nepal, and
Vietnam, 5.3 % [17••] and 3.3 % [29••] respectively. If the
target population was persons with high risk behaviors, such
as CSWs in India or IDU inmates in Indonesia, the co-
infection prevalence were lower, about 1.2~4 % [16••, 25••,
26••]. The only study among HCV seropositive blood
donors from Nepal published in 2012 showed 5.75 %
HIV-HCV co-infection rate [8••].
Risk Factors Associated with HIV-HCV Co-infection
Five cross-sectional studies were conducted among people
with obvious high risk behavior, including one study among
IDU inmates [26••], one study among HIV-positive IDUs
[27••], one study among CSWs [25••], one study among both
IDUs and CSWs [22••], and one study among HCV-positive
blood donors [8••]. Five studies estimated the role of risk
Table 1 Countries of South and Southeast Asia included in this litera-
ture-based review
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factors associated with HIV-HCV co-infection. Four cross-
sectional studies strongly indicated IDU as the highest risk
factor with a high proportion of co-infection [24••], suggested
that results were not due to chance alone, [17••, 21••] and
reported strong association in odds ratios [18••]. The only
case-control study did not find an association with IDU, rather
showing associations with age older than 50 years (OR 5.4,
95 % confidence interval (CI):1.5-19.6), the exposure to mul-
tiple parenteral infusions before the year 2000 (OR 3.4, 95 %
CI 1.5-7.6), surgery (OR 2.6, 95% CI 1.2-5.7), and fiber optic
scoping (OR 2.4, 95 % CI 1.0-5.7) [23••]. Other risk factors
associated with HIV-HCV co-infection were male sex (p<
0.001), lower CD4+ cell counts (p<0.05) [21••], and
alanine aminotransferase >40 IU/L (OR: 6.36; 95 %
CI: 1.2-32.9) [18••].
Two studies examined the association of HIV-HCV co-
infection with other outcomes, but few associations were
significant; a probable higher mortality of HIVwas noted with
HCV co-infection (adjusted hazard ratios [aHRs]=1.90; 95 %
CI: 0.98-3.7) in one cross-sectional study [29••]. One retro-
spective cohort study suggested that HIV-HCV co-infection
had no impact on morbidity, mortality, or treatment responses
to ART, as there were HIV patient deaths during 2.9 years of
follow-up, although only 7 % of HIV-HCV co-infected pa-
tients were treated for HCV infection in the case group [28••].
One study provided HIV-HCV co-infection rate but did not
analyze risk factors [16••] (Table 2):
Discussion
HIV and HCV are in completely different virus families, yet
both are transmitted through bodily fluids and blood; both
viruses can infect patients for years before symptoms are
manifested [8••]. Given the attention given to HIV, it is more
likely that HCV will be neglected; such neglect can result in
irreversible hepatocirrhosis and hepatocarcinoma [1•]. Since
1985, HIV screening has been suggested for the blood supply
and for persons at risk, with supportive public policies typi-
cally supporting this strategy. In contrast, HCV has
commanded far less attention and public policies have lagged
the need. We think the current literature does a good job
alerting the public as to the seriousness of HCV and HIV-
HCV joint infection, promoting screening and treatment pol-
icies based on a strategy to improve HCV medical care and
prevention.
HIV-HCV co-infection publications suggested wide prev-
alence variability, from 1.2 % to 98.5 % HIV-HCV co-
infection in South and Southeast Asia, notably higher among
IDUs (34.1-98.5 %). The multivariable analyses in these
cross-sectional studies confirm IDU as the major risk factor
in this region, both for HIV-HCV co-infection, and for HIV
and HCV independently. However, the case-control study in
Cambodia suggested multiple parenteral infusions before the
year 2000, surgery, and fibroscopy to be the principal risk
factors, suggesting diversity between population samples
[23••]. The lack of impact of HIV-HCV co-infection on mor-
bidity, mortality or treatment responses to ART of HIV pa-
tients in two studies [30, 31] clashes with findings from other
studies worldwide and may reflect methodological limitations
of sample size and length of follow-up.
Most countries in South and Southeast Asia are not yet
economically developed and there are strong forces towards
increasing high risk behaviors such as IDU and CSW. Basic
medical services are insufficient and often very expensive for
poor people. Furthermore, HIV prevention and control pro-
grams are often weak with inadequate attention and funding
support from national and local governments, even though
political commitments to Millennium Development Goals
(MDGs) have been declared.
The serious epidemics of HIV-HCV co-infection should be
emphasized in the prevention and treatment of both diseases in
Asia as there was less published research and fewer evidence
prevention strategies compared to Western nations. Co-
infection may accelerate the clinical progress to both diseases
[13, 31–33] and treatment success for one disease is
undermined when the other disease is neglected.
Governments have paid greater attention to HIV prevention
and control and typically provide free ARV treatment for HIV,
but the high expenses of interferon and ribavirin for HCV
treatment is still a great challenge which prohibits the access
of this clinical service, especially in these resource limited
settings of South and Southeast countries [28••]. These studies
suggest national policies, strategies, and guidelines on HIV-
HCV co-infection control should be revisited, including other
blood-borne infections, such as hepatitis B virus, GB virus C
(GBV-C), and others [23••, 27••]. Novel therapies are emerg-
ing quickly for HCV disease and countries must prepare for
the increased opportunities for HCV management that will be
emerging.
It is clear that HCV screening should be conducted as soon
as an HIV-positive test is confirmed. This permits co-infection
to be treated appropriately, quality care provided, and further
disease progress prevented [17••, 23••, 24••]. ART-naïve HIV-
infected patients may have tenofovir-based regimens given
preferentially, given its impact on both HIVand HCV, for co-
infected persons [29••]. Some unique communities, like
prisons, are recommended to pay added attention to screening,
prevention, and control of both infections and co-infection
among inmates who used or continue to use drugs [26••].
Needle and syringe exchanges, opioid substitution therapy
(especially with methadone maintenance or buprenorphine),
and condom use are all advisable for persons who use drugs,
to modulate risk from body fluid and blood-borne diseases.
The sterilization of medical instruments is critical in resource
limited settings if disposable syringe or medical consumable
Curr HIV/AIDS Rep (2014) 11:128–133 131
products are not available [34, 35]. Medical behavior should
be monitored strictly to ensure high quality services and lower
unprotected exposure to clinical HIV or HCV infections.
Proper management of HIV-HCV co-infection is critical and
can be highly effective in disease control [36]. Prevention and
control strategies should be implemented comprehensively to
ensure their maximal effectiveness.
Compliance with Ethics Guidelines
Conflict of Interest Shaodong Ye, Lin Pang, Xiaochun Wang, and
Zhongfu Liu declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1.• World Health Organization. Hepatitis C Fact Sheets. July 2013.
Available from: http://www.who.int/mediacentre/factsheets/fs164/
en/. This HCV fact sheets provided updated HCV epidemics world
widely.
2.• Joint United Nations Programme on HIV/AIDS. 2013 UNAIDS
Report on the global AIDS epidemic. December 2013. Available
from: http://www.unaids.org/en/media/unaids/contentassets/
documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_
2013_en.pdf. This report provided updated HIV epidemics world
widely.
3. Barth RE, Huijgen Q, Taljaard J, et al. Hepatitis B/C and HIV in
sub-Saharan Africa: an association between highly prevalent infec-
tious diseases. A systematic review and meta-analysis. Int J Infect
Dis. 2010;14(12):e1024–31.
4. Zhuang X, Liang Y, Chow EP, et al. HIV and HCV prevalence
among entrants to methadone maintenance treatment clinics in
China: a systematic review and meta-analysis. BMC Infect Dis.
2012;12:130.
5. Maier I, Wu GY. Hepatitis C and HIV co-infection: a review.World
J Gastroenterol. 2002;8(4):577–9.
6. Danta M, Dusheiko GM. Acute HCV in HIV-positive individuals -
a review. Curr Pharm Des. 2008;14(17):1690–7.
7. Kontorinis N, Agarwal K, Dieterich DT. Treatment of hepatitis C
virus in HIV patients: a review. AIDS. 2005;19 Suppl 3:S166–73.
8.•• Shrestha AC, Ghimire P, Tiwari BR, et al. Co-infection rate of HIV,
HBV and Syphilis among HCV seropositive identified blood do-
nors in Kathmandu, Nepal. Infect Ecol Epidemiol. 2012;2. This
study was conducted among 139 HCV seropositive blood donors
and the HIV-HCV co-infection rate was 5.75 %.
9. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis,
clinical complications, treatment, and new therapeutic technologies.
Curr HIV/AIDS Rep. 2011;8(1):12–22.
10. Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int.
2013;33 Suppl 1:63–7.
11. Agdamag DM, Kageyama S, Alesna ET, et al. Rapid spread of
hepatitis C virus among injecting-drug users in the Philippines:
implications for HIVepidemics. J Med Virol. 2005;77(2):221–6.
12. Zhao L, Feng Y, Xia XS. The different epidemic and evolution of
HCV genotypes. Yi Chuan. 2012;34(6):666–72.
13. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral
hepatitis co-infection on response to antiretroviral therapy and HIV
disease progression in the HIV-NAT cohort. AIDS. 2004;18(8):
1169–77.
14. Saravanan S, Velu V, Kumarasamy N, et al. Coinfection of hepatitis
B and hepatitis C virus in HIV-infected patients in south India.
World J Gastroenterol. 2007;13(37):5015–20.
15. Ponamgi SP, Rahamathulla S, Kumar YN, et al. Prevalence of
hepatitis C virus (HCV) coinfection in HIV infected individuals in
south India and characterization of HCV genotypes. Indian J Med
Microbiol. 2009;27(1):12–6.
16.•• Nagmoti MB, Patil CS, Jyoti MN, et al. Prevalence of hepatitis C
infection in HIV-seropositive individuals in and around Belgaum,
south India. Int J STD AIDS. 2012;23(10):e14–5. This study was
conducted among 16,124 serum samples from suspected patients
and the HIV-HCV co-infection rate was 3.52 %.
17.•• Zaw SK, Tun ST, Thida A, et al. Prevalence of hepatitis C and B
virus among patients infected with HIV: a cross-sectional analysis
of a large HIV care programme in Myanmar. Trop Doct.
2013;43(3):113–5. This study was conducted among 11,032 HIV-
infected patients and the HIV-HCV co-infection rate was 5.3 %.
18.•• Anggorowati N, Yano Y, Heriyanto DS, et al. Clinical and virolog-
ical characteristics of hepatitis B or C virus co-infection with HIV in
Indonesian patients. J Med Virol. 2012;84(6):857–65. This study
was conducted among 126 HIV patients and the HIV-HCV co-
infection rate was 34.1 %.
19. Ocama P, Seremba E. Management of HIV and hepatitis C virus
infections in resource-limited settings. Curr Opin HIV AIDS.
2011;6(6):539–45.
20. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J
Gastroenterol Hepatol. 2008;23(7 Pt 1):1000–8.
21.•• Barnawal SP, Niraula SR, Agrahari AK et al. Human immunodefi-
ciency virus and hepatitis C virus coinfection in Nepal. Indian J
Gastroenterol. 2013. This study was conducted among 313 HIV
patients and the HIV-HCV co-infection rate was 42 %.
22.•• Dunford L, Carr MJ, Dean J, et al. A multicentre molecular
analysis of hepatitis B and blood-borne virus coinfections in
Viet Nam. PLoS One. 2012;7(6):e39027. This study was
conducted among 8654 high risk individuals. 89.8 % HCV
of the HBV-HIV co-infected IDUs and 40 % HCV of HBV-
HIV co-infected CSWs were found.
23.•• Goyet S, Lerolle N, Fournier-Nicolle I, et al. Risk factors for
hepatitis C transmission in HIV patients, Hepacam Study, ANRS
12267 Cambodia. AIDS Behav. 2013. This case-control study had
44 HCV/HIV co-infected patients and 160 HIV mono-infected
patients without HCV antibodies, the risk factors associated with
co-infection included age older than 50 years, the exposure to
multiple parenteral infusions before the year 2000, surgery and
fibroscopy.
24.•• Poudel KC, Palmer PH, Jimba M, et al. Coinfection of Hepatitis C
Virus among HIV-Positive People in the Kathmandu Valley, Nepal.
J Int Assoc Provid AIDS Care. 2013. This study was conducted
among 319 HIV-positive and the HIV-HCV co-infection rate was
43.3 %.
25.•• Praseeda SD, Anuradha D, Jayanthi SS. A study on the HBV and
the HCV infections in female sex workers and their co-infection
132 Curr HIV/AIDS Rep (2014) 11:128–133
with HIV. J Clin Diagn Res. 2013;7(2):234–7. This study was
conducted among 250 CSWs and the HIV-HCV co-infection rate
was 1.2 %.
26.•• Prasetyo AA, Dirgahayu P, Sari Y, et al. Molecular epidemiology of
HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central
Javan prisons, Indonesia. J Infect Dev Ctries. 2013;7(6):453–67.
This study was conducted among 375 drug abuser inmates and the
HIV-HCV co-infection rate was 4 %.
27.•• Sereno L, Mesquita F, Kato M, et al. Epidemiology, responses, and
way forward: the silent epidemic of viral hepatitis and HIV coin-
fection in Vietnam. J Int Assoc Physicians AIDS Care (Chic).
2012;11(5):311–20. This study reviewed data of HIV in Vietnam
and the HIV-HCV co-infection rate reached 98.5 % among HIV
infected drug users.
28.•• Than NN, Sungkanuparph S, Maek-A-Nantawat W, et al.
Comparison of clinical outcomes between HIV-infected pa-
tients with and without HCV co-infection in a resource-
limited setting. Southeast Asian J Trop Med Public Health.
2012;43(3):646–51. This retrospective cohort study had 57
HIV-infected patients with HCV and 114 HIV-infected patients
without HCV. It found that HCV co-infection did not appear
to affect HIV morbidity, mortality or treatment responses to
ART.
29.•• Tsuchiya N, Pathipvanich P, Rojanawiwat A, et al. Chronic
hepatitis B and C co-infection increased all-cause mortality
in HAART-naive HIV patients in Northern Thailand.
Epidemiol Infect. 2013;141(9):1840–8. This study was con-
ducted among 700 HAART-naive HIV-infected patients and
the HIV-HCV co-infection rate was 3.3 %.
30. Vivithanaporn P, Nelles K, DeBlock L, et al. Hepatitis C virus co-
infection increases neurocognitive impairment severity and risk of
death in treated HIV/AIDS. J Neurol Sci. 2012;312(1–2):45–51.
31. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a
major cause of death among HIV infected patients: role of hepatitis
C and B viruses and alcohol. J Hepatol. 2005;42(6):799–805.
32. Rockstroh JK, Peters L, Grint D, et al. Does hepatitis C viremia or
genotype predict the risk of mortality in individuals co-infected
with HIV? J Hepatol. 2013;59(2):213–20.
33. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antire-
troviral therapy improves ESLD-free survival in HIV-HCV co-
infection. Haemophilia. 2009;15(2):552–8.
34. Szaflik J, Bełzecka-Majszyk A. Patients with HBV, HCVand HIV
antigens–medical management, surgical procedures, equipment
sterilization principles. Klin Oczna. 2003;105(6):448–52.
35. Ouzan D. Risk of transmission of hepatitis C through endoscopy of
the digestive tract. Presse Med. 1999;28(20):1091–4.
36. Santana JL, Rodríguez-Medina JR, Rodríguez-Orengo JF.
Clinical challenges and controversies in the management of
HIV/ HCV-coinfected individuals. P R Health Sci J.
2004;23(2 Suppl):35–40.
Curr HIV/AIDS Rep (2014) 11:128–133 133
